RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Jiangsu Hengrui Medicine out-licensed ex-China rights for a novel JAK inhibitor to Arcutis Pharma, a California dermatology company, in a deal worth up to $233 million, plus royalties. Arcutis will have rights to SHR0302 to treat dermatology disorders in the US, Europe and Japan. Hengrui is testing SHR0302 in a China Phase II trial for rheumatoid arthritis, though its agreement with Arcutis includes only topical use of the drug for dermatology diseases.
Source: China Biotoday
